Anzeige
Mehr »
Donnerstag, 30.04.2026 - Börsentäglich über 12.000 News
Öl bricht über $108 und Wedgemount dreht die Produktion genau jetzt wieder an
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DG50 | ISIN: IL0011839383 | Ticker-Symbol:
NASDAQ
30.04.26 | 21:27
8,250 US-Dollar
+12,02 % +0,885
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
ALPHA TAU MEDICAL LTD Chart 1 Jahr
5-Tage-Chart
ALPHA TAU MEDICAL LTD 5-Tage-Chart

Aktuelle News zur ALPHA TAU MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoAlpha Tau: Abstract zu Bauchspeicheldrüsenkrebs für ASCO-Jahrestagung angenommen1
ALPHA TAU MEDICAL Aktie jetzt für 0€ handeln
MoAlpha Tau abstract accepted at ASCO annual meeting in May2
MoAlpha Tau Medical Ltd.: Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies1
MoH.C. Wainwright reiterates Alpha Tau Medical stock rating on FDA approval1
23.04.Alpha Tau Medical Ltd.: Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane (Nab-Paclitaxel)132- IDE supplement expands trial to the other primary standard-of-care chemotherapy for pancreatic cancer patients, alongside mFOLFIRINOX - - IDE supplement also expands total trial size from 30 to...
► Artikel lesen
23.04.Alpha Tau Medical Ltd.: Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT in French Multicenter ACAPELLA Clinical Trial130ACAPELLA is the European multicenter clinical trial evaluating Alpha DaRT alpha-emitter radiotherapeutics combined with capecitabine for inoperable LAPC patients who have completed first-line mFOLFIRINOX...
► Artikel lesen
23.04.Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer1
31.03.Alpha Tau Medical Ltd.: Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT Pancreatic Cancer Data at Digestive Disease Week (DDW) 20264
31.03.Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer1
09.03.Alpha Tau Medical GAAP EPS of -$0.421
09.03.Alpha Tau Medical Ltd. - S-8, Securities to be offered to employees in employee benefit plans1
09.03.Alpha Tau Medical Ltd.: Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update2.187- Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium...
► Artikel lesen
09.03.Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer1
09.03.Alpha Tau Medical Ltd. - 20-F, Annual and transition report of foreign private issuers1
04.03.Bewertung zu hoch: Piper Sandler stuft Aktie von Alpha Tau Medical ab2
04.03.Piper Sandler cuts Alpha Tau Medical stock rating on valuation1
25.02.H.C. Wainwright raises Alpha Tau Medical price target on Japan approval1
25.02.Alpha Tau Medical: H.C. Wainwright hebt Kursziel nach Zulassung in Japan an1
24.02.Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer1
29.01.Alpha Tau Medical Ltd.: Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead365- Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ReSTART pivotal skin cancer trial as well as trials in...
► Artikel lesen
Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1